Pushing the Boundaries of RNA Innovation in Cancer and Infectious Diseases
RNA therapeutics have the potential to unlock significant advancements in treatments for infectious diseases and cancer, making them more effective, scalable and accessible than ever before.
With extensive experience in working with RNA, Tebubio product managers, Erica Cirri PhD. and Xavier Warnet PhD., explore the latest breakthroughs in RNA vaccine development and delivery in a recent article published in International Biopharmaceutical Industry (IBI). Innovations in self-amplifying RNA (saRNA) and circular (circRNA) have addressed the limitations of traditional mRNA platforms, offering improved vaccine efficacy and stability. Meanwhile, lipid nanoparticles (LNPs) are transforming RNA delivery by ensuring the stability, biodistribution and cellular uptake of fragile RNA molecules.
For support optimizing your RNA therapeutics, Tebubio's Contract Research Services (CRS) Laboratory provides high-quality, tailored solutions for RNA synthesis, delivery and expression.
Get in touch with the Tebubio team to discuss how we can help you achieve your research goals.
Originally published in International Biopharmaceutical Industry (IBI).